Investigating the role of biomarkers using liquid
Description: Investigating the role of biomarkers using liquid biopsy in diagnosis for meningiomas Stj. Dr Hasiba Karimi Mentor: Prof. Dr. Mustafa Aziz HatiboÄŸlu 14.03.22 Presentation plan Meningiomas Challenges in Diagnosis Management Liquid biopsy
Related Topics
Download Presentation
"Investigating the role of biomarkers using liquid" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Presentation Transcript
slide1. Investigating the role of biomarkers using liquid biopsy in diagnosis for meningiomas Stj. Dr Hasiba Karimi
Mentor: Prof. Dr. Mustafa Aziz HatiboÄŸlu 14.03.22<br>
slide2. Presentation plan Meningiomas
Challenges in Diagnosis & Management
Liquid biopsy
The Gap in Knowledge
Aim of the study
Method
Results
Conclusion<br>
slide3. Meningioma The most common primary brain tumor in adults
The majority of meningiomas are benign tumors (WHO I)
Diagnosed with radiological methods
No effective pharmacological intervention has been established to date
Differentiation of meningiomas from other malignancies is challenging
Imaging may not provide information on the grade of meningiomas<br>
slide4. Challenges in Diagnosis Challenges in selecting treatment choice (follow up, surgical resection, Gamma Knife) and extent of tumor resection
Only help identify the tumors when they reach a certain size
Increasing the risk of malignancy overtime
Slow growing tumors and might go undetected for years.
Tissue biopsy; for the definitive diagnosis and histological classification of meningioma;
Invasive method with effectiveness limited to stage of the tumor detected and the area that’s biopsied.
Potential morbidity<br>
slide5. Liquid biopsy Liquid biopsy is:
less invasive
more feasible
easier to repeat
providing valuable information about the tumor molecular structure and genomic dynamics. ME;, K. A. W. H. P. C. W. (n.d.). The use of microfluidic technology for cancer applications and liquid biopsy. Micromachines. Retrieved March 4, 2022, from https://pubmed.ncbi.nlm.nih.gov/30424330/<br>
slide6. Gap in Knowledge c-MYC, FABP7, GATA4 and MAOB; implicated with meningioma grades using tumor tissue samples;
Their roles in diagnosing, staging and prognosis of meningioma is unclear yet.
Have not been studied from liquid biopsy samples before.<br>
slide7. Aim of the study To identify diagnostic and prognostic potential of c-MYC, FABP7, GATA4 and MAOB in liquid biopsy samples of patients with meningioma.<br>
slide8. Materials & Method 20 patients undergoing surgery for meningioma included
May 2017 – March 2021
Tumor and serum samples from 20 meningioma patients who underwent surgical resection in Bezmialem Vakıf university Hospital
Stored at -80°C<br>
slide9. Materials & Method 15 healthy individuals used for controls.
The expression level of FABP7, GATA-4, c-MYC, and MAOB genes were evaluated with real time PCR
Patient’s clinical data including age, gender, radiological findings, simpson grade, post surgical complication and recurrence were retrospectively collected.
GraphPad Prism 3.0 was used for data analysis<br>
slide10. Demographic Information<br>
slide11. Comparision of gene expressions in serum samples between control and meningioma pateints p=0.036 Results p=0.0425 P=0.412 P=0.614<br>
slide12. Comparision of gene expressions in serum samples between Control, Grade 1, and Grade 2
meningioma pateints p=0.032
control and grade 2<br>
slide13. Comparision of gene expressions in Tumor samples between Grade 1 and Grade 2 meningioma pateints p=0.003 p=0.041 p=0.0310 P=0.120<br>
slide14. Conclusion The expression level of GATA-4, c-MYC and MAOB were statistically significant in grade II meningioma tumor samples
The expression level of MAOB was statistically significant in grade II serum samples
Our results suggested that serum expression of FABP7, GATA4, c-MYC and MAOB gene could be implemented as diagnostic marker for meningiomas
Further studies are required ;
With larger sample sizes
The implementation of biomarkers in evaluating:
recurrence probability
course of the disease<br>
slide15. References What is Meningioma? [Internet]. Meningioma Brain Tumors - Brigham and Women's Hospital. [cited 2020Dec2]. Available from: https://www.brighamandwomens.org/neurosurgery/meningioma
Sabedot TS, Malta TM, Snyder J, Walbert T, Lee I, Kalkanis S, et al. Abstract A12: DNA methylation-based liquid biopsy detects primary and recurrent meningioma [Internet]. Clinical Cancer Research. American Association for Cancer Research; 2020 [cited 2020Dec2]. Available from: https://clincancerres.aacrjournals.org/content/26/11_Supplement/A12.abstract
Palmirotta R, Lovero D, Cafforio P, Felici C, Mannavola F, Pellè E, et al. Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology [Internet]. Therapeutic advances in medical oncology. SAGE Publications; 2018 [cited 2020Dec2]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116068/
Sareen H;Garrett C;Lynch D;Powter B;Brungs D;Cooper A;Po J;Koh ES;Vessey JY;McKechnie S;Bazina R;Sheridan M;Gelder JV;Darwish B;Jaeger M;Roberts TL;De Souza P;Becker TM; The Role of Liquid Biopsies in Detecting Molecular Tumor Biomarkers in Brain Cancer Patients [Internet]. Cancers. U.S. National Library of Medicine; [cited 2020Dec2]. Available from: https://pubmed.ncbi.nlm.nih.gov/32650387/ Arneth B. Update on the types and usage of liquid biopsies in the clinical setting: a systematic review [Internet]. BMC cancer. BioMed Central; 2018 [cited 2020Dec2]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935950/
Erkan EP, Ströbel T, Dorfer C, Sonntagbauer M, Weinhäusel A, Saydam N, et al. Circulating Tumor Biomarkers in Meningiomas Reveal a Signature of Equilibrium Between Tumor Growth and Immune Modulation [Internet]. Frontiers. Frontiers; 2019 [cited 2020Dec2]. Available from: https://doi.org/10.3389/fonc.2019.01031
Ongaratti BR;Silva CB;Trott G;Haag T;Leães CG;Ferreira NP;Oliveira MC;Pereira-Lima JF;. (n.d.). Expression of MERLIN, NDRG2, ERBB2, and c-MYC in Meningiomas: Relationship with tumor grade and recurrence. Retrieved April 03, 2021, from https://pubmed.ncbi.nlm.nih.gov/27007654/
ME;, K. A. W. H. P. C. W. (n.d.). The use of microfluidic technology for cancer applications and liquid biopsy. Micromachines. Retrieved March 4, 2022, from https://pubmed.ncbi.nlm.nih.gov/30424330/
Haddad, A. F., Young, J. S., Kanungo, I., Sudhir, S., Chen, J.-S., Raleigh, D. R., Magill, S. T., McDermott, M. W., & Aghi, M. K. (1AD, January 1). Who grade I meningioma recurrence: Identifying high risk patients using histopathological features and the MIB-1 index. Frontiers. Retrieved March 4, 2022, from https://www.frontiersin.org/articles/10.3389/fonc.2020.01522/full
Dunn J;Lenis VP;Hilton DA;Warta R;Herold-Mende C;Hanemann CO;Futschik ME;. (n.d.). Integration and comparison Of Transcriptomic and proteomic data FOR Meningioma. Retrieved March 06, 2021, from https://pubmed.ncbi.nlm.nih.gov/33167358/<br>
slide16. Acknowledgment NeurosurgeryÂ
Dr. Mustafa Aziz Hatiboğlu
Kerime Akdur
Dr. Güven Gönen
Ayten Åžakarcan
Merve Çavuşoğlu
Burçe Elbasan BILSA BILSAB Brain tumor research laboratory
Dr. Mustafa Aziz Hatiboğlu
Imran Khan,PhDÂ Â
Sadaf Mahfooz, PhD
Büşra Karaçam, RA www.gammaknifeturkey.com
gk@bezmialem.edu.tr<br>
slide17. Thank you for your attention !<br>
Mentor: Prof. Dr. Mustafa Aziz HatiboÄŸlu 14.03.22<br>
slide2. Presentation plan Meningiomas
Challenges in Diagnosis & Management
Liquid biopsy
The Gap in Knowledge
Aim of the study
Method
Results
Conclusion<br>
slide3. Meningioma The most common primary brain tumor in adults
The majority of meningiomas are benign tumors (WHO I)
Diagnosed with radiological methods
No effective pharmacological intervention has been established to date
Differentiation of meningiomas from other malignancies is challenging
Imaging may not provide information on the grade of meningiomas<br>
slide4. Challenges in Diagnosis Challenges in selecting treatment choice (follow up, surgical resection, Gamma Knife) and extent of tumor resection
Only help identify the tumors when they reach a certain size
Increasing the risk of malignancy overtime
Slow growing tumors and might go undetected for years.
Tissue biopsy; for the definitive diagnosis and histological classification of meningioma;
Invasive method with effectiveness limited to stage of the tumor detected and the area that’s biopsied.
Potential morbidity<br>
slide5. Liquid biopsy Liquid biopsy is:
less invasive
more feasible
easier to repeat
providing valuable information about the tumor molecular structure and genomic dynamics. ME;, K. A. W. H. P. C. W. (n.d.). The use of microfluidic technology for cancer applications and liquid biopsy. Micromachines. Retrieved March 4, 2022, from https://pubmed.ncbi.nlm.nih.gov/30424330/<br>
slide6. Gap in Knowledge c-MYC, FABP7, GATA4 and MAOB; implicated with meningioma grades using tumor tissue samples;
Their roles in diagnosing, staging and prognosis of meningioma is unclear yet.
Have not been studied from liquid biopsy samples before.<br>
slide7. Aim of the study To identify diagnostic and prognostic potential of c-MYC, FABP7, GATA4 and MAOB in liquid biopsy samples of patients with meningioma.<br>
slide8. Materials & Method 20 patients undergoing surgery for meningioma included
May 2017 – March 2021
Tumor and serum samples from 20 meningioma patients who underwent surgical resection in Bezmialem Vakıf university Hospital
Stored at -80°C<br>
slide9. Materials & Method 15 healthy individuals used for controls.
The expression level of FABP7, GATA-4, c-MYC, and MAOB genes were evaluated with real time PCR
Patient’s clinical data including age, gender, radiological findings, simpson grade, post surgical complication and recurrence were retrospectively collected.
GraphPad Prism 3.0 was used for data analysis<br>
slide10. Demographic Information<br>
slide11. Comparision of gene expressions in serum samples between control and meningioma pateints p=0.036 Results p=0.0425 P=0.412 P=0.614<br>
slide12. Comparision of gene expressions in serum samples between Control, Grade 1, and Grade 2
meningioma pateints p=0.032
control and grade 2<br>
slide13. Comparision of gene expressions in Tumor samples between Grade 1 and Grade 2 meningioma pateints p=0.003 p=0.041 p=0.0310 P=0.120<br>
slide14. Conclusion The expression level of GATA-4, c-MYC and MAOB were statistically significant in grade II meningioma tumor samples
The expression level of MAOB was statistically significant in grade II serum samples
Our results suggested that serum expression of FABP7, GATA4, c-MYC and MAOB gene could be implemented as diagnostic marker for meningiomas
Further studies are required ;
With larger sample sizes
The implementation of biomarkers in evaluating:
recurrence probability
course of the disease<br>
slide15. References What is Meningioma? [Internet]. Meningioma Brain Tumors - Brigham and Women's Hospital. [cited 2020Dec2]. Available from: https://www.brighamandwomens.org/neurosurgery/meningioma
Sabedot TS, Malta TM, Snyder J, Walbert T, Lee I, Kalkanis S, et al. Abstract A12: DNA methylation-based liquid biopsy detects primary and recurrent meningioma [Internet]. Clinical Cancer Research. American Association for Cancer Research; 2020 [cited 2020Dec2]. Available from: https://clincancerres.aacrjournals.org/content/26/11_Supplement/A12.abstract
Palmirotta R, Lovero D, Cafforio P, Felici C, Mannavola F, Pellè E, et al. Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology [Internet]. Therapeutic advances in medical oncology. SAGE Publications; 2018 [cited 2020Dec2]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116068/
Sareen H;Garrett C;Lynch D;Powter B;Brungs D;Cooper A;Po J;Koh ES;Vessey JY;McKechnie S;Bazina R;Sheridan M;Gelder JV;Darwish B;Jaeger M;Roberts TL;De Souza P;Becker TM; The Role of Liquid Biopsies in Detecting Molecular Tumor Biomarkers in Brain Cancer Patients [Internet]. Cancers. U.S. National Library of Medicine; [cited 2020Dec2]. Available from: https://pubmed.ncbi.nlm.nih.gov/32650387/ Arneth B. Update on the types and usage of liquid biopsies in the clinical setting: a systematic review [Internet]. BMC cancer. BioMed Central; 2018 [cited 2020Dec2]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935950/
Erkan EP, Ströbel T, Dorfer C, Sonntagbauer M, Weinhäusel A, Saydam N, et al. Circulating Tumor Biomarkers in Meningiomas Reveal a Signature of Equilibrium Between Tumor Growth and Immune Modulation [Internet]. Frontiers. Frontiers; 2019 [cited 2020Dec2]. Available from: https://doi.org/10.3389/fonc.2019.01031
Ongaratti BR;Silva CB;Trott G;Haag T;Leães CG;Ferreira NP;Oliveira MC;Pereira-Lima JF;. (n.d.). Expression of MERLIN, NDRG2, ERBB2, and c-MYC in Meningiomas: Relationship with tumor grade and recurrence. Retrieved April 03, 2021, from https://pubmed.ncbi.nlm.nih.gov/27007654/
ME;, K. A. W. H. P. C. W. (n.d.). The use of microfluidic technology for cancer applications and liquid biopsy. Micromachines. Retrieved March 4, 2022, from https://pubmed.ncbi.nlm.nih.gov/30424330/
Haddad, A. F., Young, J. S., Kanungo, I., Sudhir, S., Chen, J.-S., Raleigh, D. R., Magill, S. T., McDermott, M. W., & Aghi, M. K. (1AD, January 1). Who grade I meningioma recurrence: Identifying high risk patients using histopathological features and the MIB-1 index. Frontiers. Retrieved March 4, 2022, from https://www.frontiersin.org/articles/10.3389/fonc.2020.01522/full
Dunn J;Lenis VP;Hilton DA;Warta R;Herold-Mende C;Hanemann CO;Futschik ME;. (n.d.). Integration and comparison Of Transcriptomic and proteomic data FOR Meningioma. Retrieved March 06, 2021, from https://pubmed.ncbi.nlm.nih.gov/33167358/<br>
slide16. Acknowledgment NeurosurgeryÂ
Dr. Mustafa Aziz Hatiboğlu
Kerime Akdur
Dr. Güven Gönen
Ayten Åžakarcan
Merve Çavuşoğlu
Burçe Elbasan BILSA BILSAB Brain tumor research laboratory
Dr. Mustafa Aziz Hatiboğlu
Imran Khan,PhDÂ Â
Sadaf Mahfooz, PhD
Büşra Karaçam, RA www.gammaknifeturkey.com
gk@bezmialem.edu.tr<br>
slide17. Thank you for your attention !<br>